All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1600+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Astellas' Izervay (complement C5 inhibitor) label update application gets the FDA expedited review treatment
RNA aptamer, geographic atrophy - Read more

THE GOOD
Business Development

Climb Bio in-licenses MIL116 (anti-APRIL) antibody from Beijing Mabworks, with development + commercial rights to territories outside of greater China
Monoclonal antibody, IgA nephropathy - Read more

THE GOOD
Clinical Trials

Sanofi's subcutaneous Sarclisa (targeting CD38) matches intravenous version in Ph3 trial for multiple myeloma treatment
Monoclonal antibody, multiple myeloma, cancer - Read more

Bayer's elinzanetant, (targeting NK3, NK1) delivers positive Ph3 data for trial for hot flashes in breast cancer patients receiving endocrine therapy
Small molecule, vasomotor symptoms, hot flashes, breast cancer - Read more

Tenpoint Therapeutics showcases positive Ph3 results for Brimochol PF (carbachol/brimonidine) eye drops in improving vision in presbyopia patients
Small molecule, emmetropic phakic presbyopia, pseudophakic presbyopia - Read more

PRESENTED BY YOU?
Get the attention of 1600+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Company Launches

Verdiva Bio secures massive $410M Series A funding to develop weekly weight loss drug, marking major UK biotech investment.
Small molecule, GLP-1, obesity - Read more

Light Horse Therapeutics launches with $62M Series A to fund “Function-first” small molecule discovery engine
Small molecule, cancer, drug discovery - Read more

RheumaGen launches with $15M Series A funding to develop gene-editing therapies for autoimmune diseases, starting with rheumatoid arthritis treatment
Gene-editing, rheumatoid arthritis, arthritis - Read more

THE GOOD
Fundraises

Coave Therapeutics $33M Series A, developing targeted delivery platform for genetic medicines
Gene therapy, drug delivery, viral vector - Read more

AnaCardio SEK 205M ($18.4M) Series A extension, small molecule treating heart failure
Small molecule, heart failure - Read more

A2 Biotherapeutics $80M Series C, developing “logic-gated” cell therapies for cancer
Cell therapy, solid tumor, pancreatic cancer, lung cancer, ovarian cancer - Read more

Numab Therapeutics CHF 50M ($55M) Series C extension, multi-specific antibodies for immunology and oncology
T-cell engager, solid tumor, cancer, multi-specific antibody - Read more

Leyden Labs $70M fundraise, Dutch biotech developing mucosal protection against respiratory viruses like flu
Nasal spray, influenza, COVID-19 - Read more

RyboDyn $4M Pre-Seed, biotech company developing dark genome immunotherapies for drug development
Immunotherapy, drug discovery, dark genome - Read more

Thetis Pharmaceuticals $8.975M investment loan, funds to support Phase 1b trial of oral IBD treatment hopeful TP-317 (BLT1 agonist)
Small molecule, inflammatory bowel disease - Read more

Calidi Biotherapeutics public offering (undisclosed amount), oncolytic viruses targeting high-grade gliomas and solid tumors
Oncolytic virus, glioma, solid tumor, cancer - Read more

Grove AI raises $4.9M Seed round to develop AI-powered clinical trial management platform
Clinical trial management, AI, software - Read more

THE GOOD
Lawsuits

Catalyst Pharmaceuticals and Teva Pharmaceuticals settle patent dispute over generic version of Firdapse
Small molecule, Lambert-Eaton myasthenic syndrome, generic - Read more

THE GOOD
Mergers & Acquisitions

Vividion Therapeutics acquires Tavros Therapeutics, enhancing drug discovery capabilities in oncology and immunology research.
Small molecule, cancer, drug discovery, immune disorder, synthetic lethality - Read more

GSK rumored to be in advanced talks to acquire IDRx for $1B, potential announcement during upcoming JP Morgan Healthcare Conference
Small molecule, gastrointestinal stromal tumours, cancer - Read more

THE GOOD
Partnerships

Synaffix (Lonza subsidiary), Boehringer Ingelheim partner to develop next-gen ADCs for cancer treatment
Antibody-drug conjugate, cancer, drug development - Read more

Alchemab Therapeutics, Eli Lilly partner to discover next-gen ALS-treating antibodies via assessing patient samples with “unusually slow rates of [ALS] disease progression“
Antibody, amyotrophic lateral sclerosis, drug discovery - Read more

Biocytogen, SOTIO Biotech partner to develop ADC therapy SOT109 for colorectal cancer using former’s human antibodies
Antibody-drug conjugate, colorectal cancer, drug development - Read more

Dropshot Therapeutics, Etherna Immunotherapies partner to develop RNA therapeutics via combining both partners’ platform technologies
RNA, heart disease, kidney disease, drug delivery, drug development - Read more

Bristol Myers Squibb, Medidata extend partnership for clinical trial platform and AI tools to enhance research efficiency
Clinical trial management, AI - Read more

AMD invest $20M in and partners with Absci and AI-powered antibody drug discovery
Antibody, drug discovery, AI - Read more

Samsung Biologics, LigaChem Bio partner to develop and manufacture ADC in “win-win” collaboration
Antibody-drug conjugate, cancer, drug development, manufacturing - Read more

THE GOOD
Patient Access

Medicare plans now cover Eli Lilly's obesity drug Zepbound for sleep apnea patients, potentially adding $1.4B to peak revenue.
GLP-1, obesity, sleep apnea - Read more

THE GOOD
Product Launches

Astraveus achieves first “end-to-end” automated CAR-T cell production using microfluidic technology, promising lower costs and higher efficiency.
Cell therapy, manufacturing, CAR-T - Read more

Found launches $189 oral semaglutide tablets as cheaper alternative to injectable GLP-1 weight loss medications
GLP-1, obesity - Read more

THE GOOD
Research

Scientists develop promising gene editing therapy using base editing technology to treat Stargardt disease
Gene-editing, Stargardt disease, inherited macular degeneration - Read more

Penn Engineering develops mvGPT technology enabling simultaneous gene editing, activation, and repression for disease treatment and research
Gene-editing, biology tools - Read more

Columbia researchers develop AI model that predicts gene activity in human cells, similar to how ChatGPT processes language
Gene activity prediction, gene expression prediction, AI - Read more

THE GOOD
Strategic Plans

Windtree Therapeutics plans to acquire small biotech companies with FDA-approved products in bid to become a “revenue-generating biotechnology company“
M&A strategy - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Layoffs

Intellia Therapeutics cuts 27% of workforce and discontinues early-stage programs to focus on two lead rare disease candidates
Gene-editing, hereditary angioedema, transthyretin amyloidosis with cardiomyopathy, hereditary transthyretin amyloidosis with polyneuropathy - Read more

IGM Biosciences discontinues two autoimmune drugs after poor trial results, plans to lay off 75% of workforce
Bispecific antibody, rheumatoid arthritis, lupus - Read more

Shoreline Biosciences lays off staff working on Kite Pharma (Gilead) cell therapy project, partnership's future uncertain
Cell therapy, cancer - Read more [Paywall]

THE UGLY
Regulatory

Vanda Pharmaceuticals blasts FDA's leadership after rejection of gastroparesis drug tradipitant (NK-1R blocker), citing lack of transparency in decision-making
Small molecule, gastroparesis - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here